It’s not the when, it’s the how.
Yesterday after Abbott reported results this appeared in a post on the Fierce Biotech web site.
“The strong performance in diabetes tech sales may go a long way in outweighing Abbott’s losses in COVID testing, according to Third Bridge senior analyst George Congdon, who wrote of the department’s earnings, “This news is particularly well received given the FDA’s 2023 clearance of the Freestyle Libre 2 and 3 sensors to integrate with autonomous insulin delivery systems, which will pave the way for Abbott to partner with Insulet’s newly launched Omnipod 5 insulin pump, the current standard of . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.